AZALIEVA 100 mg contains Azacitidine, a hypomethylating agent and pyrimidine nucleoside analogue. It incorporates into DNA and RNA, leading to inhibition of DNA methyltransferase, reactivation of tumor suppressor genes, and normalization of bone marrow function. It is mainly used in myelodysplastic syndromes (MDS).

Azacitidine is indicated for:

1. Myelodysplastic Syndromes (MDS)
     – Including refractory anemia, RAEB, and CMML

2. Acute Myeloid Leukemia (AML)
    – Especially in elderly or unfit patients

3. Chronic Myelomonocytic Leukemia (CMML)

Common side effects:

•  Myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Injection site reactions

•  Fatigue

Other side effects:

•  Diarrhea, constipation

•  Fever

Serious side effects:

•  Severe infections

•  Renal toxicity (rare)

•  Hepatic impairment (rare)

 Monitor CBC before each cycle and manage cytopenias appropriately.

Dosage is based on body surface area (BSA).

Standard dosing:

•  75 mg/m²/day

•  Given subcutaneously or IV for 7 consecutive days

•  Cycle repeated every 28 days

100 mg vial is commonly used for adult dosing.

NOTE: This medicine should be taken only under a doctor’s supervision.